UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PROTAC therapy as a new targeted therapy for lung cancer

Molecular therapy, 2023-03, Vol.31 (3), p.647-656

2023

Volltextzugriff (PDF)

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

Nature medicine, 2021-08, Vol.27 (8), p.1410-1418

2021

Volltextzugriff (PDF)

cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth

The Journal of clinical investigation, 2016-06, Vol.126 (6), p.2267-2279

2016

Volltextzugriff (PDF)

TYMS promotes genomic instability and tumor progression in Ink4a/Arf null background

Oncogene, 2023-06, Vol.42 (23), p.1926-1939

2023

Volltextzugriff (PDF)

Re: a cancer theory kerfuffle can lead to new lines of research

JNCI : Journal of the National Cancer Institute, 2015-03, Vol.107 (5), p.djv060-djv060

Kaye, Frederic J

2015

Volltextzugriff (PDF)

CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells

Oncogene, 2018-04, Vol.37 (14), p.1885-1895

2018

Volltextzugriff (PDF)

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Clinical cancer research, 2020-01, Vol.26 (2), p.439-449

2020

Volltextzugriff (PDF)

Mutation-associated fusion cancer genes in solid tumors

Molecular cancer therapeutics, 2009-06, Vol.8 (6), p.1399-1408

Kaye, Frederic J

2009

Volltextzugriff (PDF)

Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma

JNCI : Journal of the National Cancer Institute, 2015-01, Vol.107 (1), p.378-dju378

2015

Volltextzugriff (PDF)

Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors

JNCI : Journal of the National Cancer Institute, 2015-08, Vol.107 (8), p.djv123

2015

Volltextzugriff (PDF)

Managing stage 4 ameloblastoma with dual BRAF/MEK inhibition: A case report with 8-year clinical follow-up

Oral oncology, 2022-05, Vol.128, p.105854, Article 105854

2022

Volltextzugriff (PDF)

Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival

The Journal of clinical investigation, 2019-06, Vol.129 (6), p.2279-2292

2019

Volltextzugriff (PDF)

hSETD1A Regulates Wnt Target Genes and Controls Tumor Growth of Colorectal Cancer Cells

Cancer research (Chicago, Ill.), 2014-02, Vol.74 (3), p.775-786

2014

Volltextzugriff (PDF)

PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

Cells (Basel, Switzerland), 2024-03, Vol.13 (6), p.528

2024

Volltextzugriff (PDF)

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition

Oncotarget, 2018-12, Vol.9 (100), p.37352-37366

2018

Volltextzugriff (PDF)

Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer

JNCI : Journal of the National Cancer Institute, 2019-07, Vol.111 (7), p.664-674

2019

Volltextzugriff (PDF)

Delta‐Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma

The oncologist (Dayton, Ohio), 2020-09, Vol.25 (9), p.810-817

2020

Volltextzugriff (PDF)

RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer: Lung cancer

Oncogene, 2002-10, Vol.21 (45), p.6908-6914

KAYE, Frederic J

2002

Volltextzugriff (PDF)

Cetuximab‐associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck

Head & neck, 2019-04, Vol.41 (4), p.E55-E58

2019

Volltextzugriff (PDF)

Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation

eLife, 2021-06, Vol.10

2021

Volltextzugriff (PDF)

Disparities Contributing to Late-Stage Diagnosis of Lung, Colorectal, Breast, and Cervical Cancers: Rural and Urban Poverty in Florida

Cancers, 2023-10, Vol.15 (21), p.5226

2023

Volltextzugriff (PDF)

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Science (American Association for the Advancement of Science), 2004-06, Vol.304 (5676), p.1497-1500

2004

Volltextzugriff (PDF)

MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma

Oral oncology, 2019-11, Vol.98, p.147-155

2019

Volltextzugriff (PDF)

Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice

Cell death discovery, 2023-01, Vol.9 (1), p.1-10, Article 1

2023

Volltextzugriff (PDF)

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Journal of hematology and oncology, 2022-03, Vol.15 (1), p.23-23, Article 23

2022

Volltextzugriff (PDF)

1 – 25 von 325

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(192)
Mit Volltextzugriff
(305)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PROTAC therapy as a new targeted therapy for lung cancer

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth

TYMS promotes genomic instability and tumor progression in Ink4a/Arf null background

Re: a cancer theory kerfuffle can lead to new lines of research

CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Mutation-associated fusion cancer genes in solid tumors

Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma

Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors

Managing stage 4 ameloblastoma with dual BRAF/MEK inhibition: A case report with 8-year clinical follow-up

Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival

hSETD1A Regulates Wnt Target Genes and Controls Tumor Growth of Colorectal Cancer Cells

PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition

Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer

Delta‐Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma

RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer: Lung cancer

Cetuximab‐associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck

Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation

Disparities Contributing to Late-Stage Diagnosis of Lung, Colorectal, Breast, and Cervical Cancers: Rural and Urban Poverty in Florida

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma

Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Suchergebnisse filtern